Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Ovid Therapeutics (OVID).
Ovid Therapeutics Inc. has announced that Thomas Perone, previously serving as General Counsel, Chief Compliance Officer and Corporate Secretary, will be departing the company due to workforce reduction but will remain as a consultant until January 2025. Under the new Consulting Agreement, Perone will be paid up to $55,000 and his equity awards will continue to vest through the consulting term, alongside agreeing to certain post-termination restrictions including non-solicitation.
Find detailed analytics on OVID stock on TipRanks’ Stock Analysis page.
